Pediatric Atopic Dermatitis
‘Will make life better’: FDA advances Zoryve cream 0.05% for pediatric atopic dermatitis
The FDA has accepted the supplemental new drug application for Zoryve cream 0.05% to treat mild to moderate atopic dermatitis in children aged 2 to 5 years, according to a press release from the manufacturer.
Moderate-to-Severe Atopic Dermatitis: Optimizing Care Across Specialties
This activity is supported by an educational grant from Sanofi and Regeneron Pharmaceuticals.
Mastering Hand and Foot Atopic Dermatitis: From Immunology to Innovative Treatments
This activity is supported by an educational grant from Sanofi and Regeneron Pharmaceuticals.
‘Follow the science and follow your gut’ to make a change in medicine
Emma Guttman-Yassky, MD, PhD, lives her life in dichotomy. She’s a dermatologist and an immunologist; a researcher and a department chair; and her medical and research experience transcends the globe, from North America to Europe.
Ruxolitinib cream 1.5% exhibits long-term safety in pediatric atopic dermatitis
Year-long ruxolitinib cream 1.5% treatment among children aged 2 to 11 years with extensive moderate to severe atopic dermatitis is safe, according to results presented at the Revolutionizing Atopic Dermatitis Conference.
Moderate-to-Severe Atopic Dermatitis: Separating Fact From Myth in Primary Care
This activity is supported by an educational grant from Sanofi and Regeneron Pharmaceuticals.
Getting Under the Skin: Updates in the Treatment of Pediatric Atopic Dermatitis
This activity is supported by an educational grant from Sanofi and Regeneron Pharmaceuticals.
Methotrexate shows longer efficacy in pediatric atopic dermatitis than cyclosporine
Both methotrexate and cyclosporin are efficacious in the treatment of severe pediatric atopic dermatitis, but methotrexate showed higher rates of sustained treatment response, according to a study.
Dupilumab shows long-term safety, efficacy in children, adolescents with atopic dermatitis
Children and adolescents with atopic dermatitis treated with long-term dupilumab showed positive results and acceptable safety, according to a meta-analysis of multiple studies.
AB-101a rapidly reduces itch in patients aged as young as 2 years with atopic dermatitis
Alphyn Biologics announced new data from its phase 2a clinical trial evaluating topical AB-101a for the treatment of mild to moderate atopic dermatitis in patients aged as young as 2 years, according to a company release.